Fluorescence-guided surgery can enhance the surgeon's ability to achieve a complete oncologic resection. There are a number of tumor-specific probes being developed with many preclinical mouse models to evaluate their efficacy. The current review discusses the different preclinical mouse models in the setting of probe evaluation and highlights the advantages of patient-derived orthotopic xenografts (PDOX) mouse models and genetic reporters to develop fluorescence-guided surgery. 
| INTRODUCTION
The primary goal of curative surgical resection of cancer is the complete removal of all neoplastic tissues while limiting damage to normal surrounding structures. The completeness of surgical resection affects outcomes and can provide cures in localized cases. To achieve this goal, clear visualization of the lesion is critical.
Traditional techniques of palpation and visual inspection with white light are insufficient. [1] [2] [3] Intraoperative navigation using fluorescence guidance is a high-contrast real-time method of visualization that enhances the surgeon's ability to remove all cancerous tissues. 4, 5 While there are several food and drug administration (FDA)-approved fluorescent dyes such as fluorescein, methylene blue, and indocyanine green, they rely on an enhanced permeability and retention effect of tumors and are generally not sufficiently specific for oncologic use. 6 Tumor-specific fluorescence is necessary for complete oncologic resection, and this can be delivered through fluorophore-conjugated probes or viral vector delivery and expression of fluorescent proteins.
A number of preclinical animal models have been developed to evaluate tumor-specific fluorescence. Here, we address the advantages of patient-derived orthotopic (PDOX) mouse models and genetic reporters to develop fluorescence-guided surgery (FGS).
2 | BACKGROUND
| Subcutaneous mouse tumor models
Since the first description of the ability of nude mice to bear human tumors by Rygaard 
| Experimental metastasis models
Methods such as intravenous, splenic, footpad, or intracardiac injections of cancer cells have been attempted to model the metastatic cascade, but it is generally accepted that mouse models using these approaches are not physiologic. 13 These experimental metastasis models only demonstrate the last few steps of metastasis:
the entry of tumor cells into circulation, arrest in capillary beds, extravasation, survival, and proliferation in secondary sites. 14 While these injected tumor cells reach many organs, just the presence of a viable tumor cell within an organ will not guarantee development of a metastasis. 15 With the exception of intracardiac injections that can form widespread metastases, these various approaches usually form metastases at limited sites, such as liver for splenic injection or lung for intravenous injections. They usually require the use of a sequentially-selected metastatic population of a given cell line to improve efficacy, often overestimating the malignant phenotype. 16 
| Genetically-engineered mouse models
Genetically-engineered mouse models with or without induction using organotropic carcinogens are also potential models of tumorigenesis, often showing lesions similar to humans from adenomas to carcinomas. These mouse models are driven by highly over-expressed promoters, often require a long period of latency before developing tumors, and the lesions are often at nonphysiologic locations; for example, the small bowel in APC-knockout mice used to study colon cancer. 17, 18 However, they can be viable models for evaluating tumor-specific fluorescence agents when thoughtfully paired with the appropriate mouse model. For example, KIT K641E+/− transgenic mice with spontaneous development of cecal gastro-intestinal stromal tumors (GISTs) were used to evaluate an anti-c-kit antibody tagged to an AlexaFlour488 nm dye. 19 The fluorescent probe was able to detect cecal lesions with a positive predictive value of 85%, negative predictive value of 100%, with a specificity of 87%, and a sensitivity of 100%. It is important to note that besides the known driver mutation in genetically-engineered mouse models, the tumors formed are usually missing other key mutations and antigens that are often present in human cancers.
They are unable to clearly reflect the diverse spectrum of genetic aberrations found in human tumors, which can be a drawback when these mutations are targets for fluorescence. 16, 20 Other 
| Orthotopic mouse tumor models
Orthotopic implantation of tumors, placement based on the corresponding site from which the original carcinoma grew in the patient, is based on 
| Other animal models
Aside from the mouse model, other animals have been used for evaluating advancements in FGS. Animals such as rats, guinea pigs, rabbits, dogs, or pigs can be used, but have drawbacks in cancer modeling. these larger animal models cannot effectively model human cancers, the development advanced reproductive technologies and the ability to introduce genome modifications through approaches such as CRISPR, larger oncologic animal models such as the oncopig will become available. 43 In evaluating tumor-specific fluorescent probes, these larger animal models may be time and resource limiting, and their use is carefully considered.
| Surgical orthotopic implantation
Our laboratory has developed the technique of surgical orthotopic implantation (SOI) of tumor fragments in a number of cancers. Rather than the injection of dissociated cells, which may disrupt tumor integrity, implantation of histologically intact tissue blocks using microsurgical techniques is used. 44, 45 Creating these models can be time and resource intensive, as microsurgical skills are necessary and the tumor growth can be difficult to follow noninvasively.
| Patient-derived orthotopic xenografts (PDOX)
Implantation of patient-derived xenografts into their orthotopic location is the approach that best recapitulates the tumor microenvironment and the metastatic cascade. 50 and sarcomas. 51 PDOX models can have limitations that they are usually implanted in nude mice; therefore, the evaluation of an immune response is limited. In these cases, xenografts could be implanted into humanized mice. 65 and melanoma. 66 The approach of adenovirus-mediated genetic labeling using a fluorescent EGFR antibodies initially conjugated with Cy5.5 were studied. 85 This has since then advanced into studies of fully human anti-EGFR antibody conjugated with the near infrared (NIR) fluorophore IRDye800. 86 The results of the studies in orthotopic mouse models have been translated into a number of clinical trials using these probes for FGS in gastrointestinal cancers and head and neck cancers (NCT02784028, NCT02973672, NCT01987375, NCT02736578, NCT03384238). 87, 88 These approaches require imaging past several days and required repeat administration of the agent for a strong fluorescence signal.
| Orthotopic mouse models to demonstrate outcomes of FGS
Compared with genetic labeling with viral vectors that retains a persistent signal, this approach is not able to detect tumor recurrences or future metastases. An advantage is that a number of fluorophore and antibody combinations could potentially be used, including near-infrared wavelength dyes that can penetrate at increased tissue depth.
Fluorescent genetic labeling is limited to the wavelengths of fluorescent protein which emit signals at visible wavelengths. However, the visible wavelengths are detectable by the human eye and do not need a dedicated detector to capture the fluorescence signal, which can be an issue with near-infrared dyes. (Table 1) 2.13 | Other approaches to tumor-specific fluorophore delivery
Delivery of tumor-specific fluorescence is not limited to viral reporters and antibody conjugates. While it is beyond the scope of this review on preclinical mouse models to discuss the available probe platforms, a summary is included with recommended references in Table 2 . These probes have been evaluated for in vivo fluorescence in both subcutaneous and orthotopic nude mouse xenograft models, with some are progressing into clinical trials.
LWIN ET AL. T A B L E 2 Approaches to delivery of in-situ tumor-specific fluorescence for FGS FGS, fluorescence-guided surgery; GI, gastrointestinal.
Activatable probes such as γ-glutamyl hydroxymethyl rhodamine green or ratiometric activatable cell-penetrating peptides carry quenched fluorophores that are released on encountering tumor-specific enzymes.
γ-glutamyl hydroxymethyl rhodamine green has been evaluated in ex vivo patient samples (UMIN000003655) while ratiometric activatable cellpenetrating peptides have been translated from animal studies to a phase I breast cancer clinical trial (NCT02391194, NCT03113825). 89, 91, 106 Small molecules or peptides conjugated to fluorophores can be designed to target specific pockets or motifs that are overexpressed in specific malignancies. EGFR is overexpressed in head and neck cancers and Keereweer et al 107 used a recombinant epidermal growth factor molecule conjugated to IRDye800 to target these receptors in an orthotopic oral cancer model. The OSC-19-luc CDX was used; when implanted in the orthotopic location, it was capable of lymph node metastases. The CW800-EGF probe was able to highlight not only the primary tumor on the tongue but also the draining lymph nodes, confirmed by histology. 
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